[{"command":"openDialog","selector":"#drupal-modal","settings":null,"data":"\u003Cdiv id=\u0022republish_modal_form\u0022\u003E\u003Cform class=\u0022modal-form-example-modal-form ecl-form\u0022 data-drupal-selector=\u0022modal-form-example-modal-form\u0022 action=\u0022\/it\/article\/modal\/7375\u0022 method=\u0022post\u0022 id=\u0022modal-form-example-modal-form\u0022 accept-charset=\u0022UTF-8\u0022\u003E\u003Cp\u003EHorizon articles can be republished for free under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.\u003C\/p\u003E\n      \u003Cp\u003EYou must give appropriate credit. We ask you to do this by:\u003Cbr \/\u003E\n      1) Using the original journalist\u0027s byline\u003Cbr \/\u003E\n      2) Linking back to our original story\u003Cbr \/\u003E\n      3) Using the following text in the footer: This article was originally published in \u003Ca href=\u0027#\u0027\u003EHorizon, the EU Research and Innovation magazine\u003C\/a\u003E\u003C\/p\u003E\n      \u003Cp\u003ESee our full republication guidelines \u003Ca href=\u0027\/horizon-magazine\/republish-our-stories\u0027\u003Ehere\u003C\/a\u003E\u003C\/p\u003E\n      \u003Cp\u003EHTML for this article, including the attribution and page view counter, is below:\u003C\/p\u003E\u003Cdiv class=\u0022js-form-item form-item js-form-type-textarea form-item-body-content js-form-item-body-content ecl-form-group ecl-form-group--text-area form-no-label ecl-u-mv-m\u0022\u003E\n        \n\u003Cdiv\u003E\n  \u003Ctextarea data-drupal-selector=\u0022edit-body-content\u0022 aria-describedby=\u0022edit-body-content--description\u0022 id=\u0022edit-body-content\u0022 name=\u0022body_content\u0022 rows=\u00225\u0022 cols=\u002260\u0022 class=\u0022form-textarea ecl-text-area\u0022\u003E\u003Ch2\u003E\u2018Never seen anything as effective\u2019 \u2013 the not-so-new-drug repurposed for a rare disease\u003C\/h2\u003E\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\n\n\u003Cp\u003EThe disease, also known as AKU, prevents the breakdown of a chemical called homogentisic acid in the body. The kidneys help to clear this chemical and get rid of it through urine. When exposed to the air, it turns black and this is how parents usually spot the first sign of the condition in children.\u003C\/p\u003E\n\n\u003Cp\u003EHowever, some of the homogentisic acid remains in the body and builds up slowly over time. This starts to cause damage in the areas that it accumulates, such as the cartilage and heart valves.\u003C\/p\u003E\n\n\u003Cp\u003E\u2018Similar symptoms appear in most patients, with spinal problems in their 20s or 30s, then severe joint deterioration during their 30s, 40s and 50s, and then heart problems in their 50s and later,\u2019 said Nick Sireau, CEO of the \u003Ca href=\u0022https:\/\/akusociety.org\/\u0022 rel=\u0022noopener noreferrer\u0022 target=\u0022_blank\u0022\u003EAKU Society\u003C\/a\u003E in the UK.\u003C\/p\u003E\n\n\u003Cp\u003ESireau has two sons with AKU, which prompted his interest in the condition. AKU affects about one in a million people, who each have two defective copies of a gene called HGD. That means that Sireau\u2019s sons inherited defective HGD genes from him and their mother, both of whom are genetic carriers with no symptoms.\u003C\/p\u003E\n\n\u003Cp\u003E\u2018We were quite fortunate because they were diagnosed at birth. Our eldest is 20 years old and our other son is 17,\u2019 said Sireau. \u2018The only symptoms they\u2019ve really had is the urine going red-black.\u003C\/p\u003E\n\n\u003Cp\u003E\u2018For us, the parents, it has had obviously much more of an impact, because I\u2019ve been now working on this for 17 years. It\u2019s become my job.\u2019\u003C\/p\u003E\n\n\u003Cp\u003E\u003Cblockquote class=\u0022text-center text-blue font-bold text-2xl w-full lg:w-1\/2 border-2 border-blue p-12 my-8 lg:m-12 lg:-ml-16 float-left\u0022\u003E\n  \u003Cspan class=\u0022text-5xl rotate-180\u0022\u003E\u201c\u003C\/span\u003E\n  \u003Cp class=\u0022font-serif italic\u0022\u003E\u2018Patients are delighted. People feel a reduction in pain, and they feel that the evolution of their AKU is slowing.\u2019\u003C\/p\u003E\n  \u003Cfooter\u003E\n    \u003Ccite class=\u0022not-italic font-normal text-sm text-black\u0022\u003ENick Sireau, CEO, AKU Society\u003C\/cite\u003E\n  \u003C\/footer\u003E\n\u003C\/blockquote\u003E\n\u003C\/p\u003E\n\n\u003Cp\u003E\u003Cstrong\u003ETantalising\u003C\/strong\u003E\u003C\/p\u003E\n\n\u003Cp\u003EThe AKU Society has helped to fund research into the condition, as there were no treatments available. Many patients need joint and heart valve replacement surgery as the symptoms progress. However, the promise of a new treatment has remained tantalisingly on the horizon for almost two decades, says Sireau.\u003C\/p\u003E\n\n\u003Cp\u003E\u2018When my first son was diagnosed, we went to Great Ormond Street (a children\u2019s hospital in London, UK) and had a meeting with a consultant who said there was really not much we could do, but there was the potential of a treatment in the next 10 years or so but that it was very, very early stage. That\u2019s when we heard about nitisinone and that the National Institutes of Health in America was starting to look at it for AKU.\u2019\u003C\/p\u003E\n\n\u003Cp\u003ENitisinone is a drug already in use for another disease called HT-1 and scientists thought it could also help with AKU. Unfortunately, the NIH trial run was inconclusive, so US Food and Drug Administration did not approve the drug for AKU.\u003C\/p\u003E\n\n\u003Cp\u003E\u2018If you\u2019ve got a failed trial, it\u2019s difficult to find a backer for a further clinical trial in an ultra-rare disease because there\u2019s not much money going around,\u2019 said Professor Lakshminarayan Ranganath, an AKU specialist at Royal Liverpool University Hospital in the UK.\u003C\/p\u003E\n\n\u003Cp\u003EHowever, Prof. Ranganath was confident that the drug would work; it just needed to be tested more rigorously. The NIH trial had only tried the drug in 20 people with a low dose and had based the results on changes in hip flexibility, which he says \u2018we thought was na\u00efve and inappropriate for a complex multi-system disease, which is very slowly progressive.\u2019\u003C\/p\u003E\n\n\u003Cp\u003ECollaborating with AKU experts from several European countries, Prof. Ranganath coordinated the \u003Ca href=\u0022https:\/\/cordis.europa.eu\/project\/id\/304985\u0022 rel=\u0022noopener noreferrer\u0022 target=\u0022_blank\u0022\u003EDevelopAKUre\u003C\/a\u003E study, which included \u003Ca href=\u0022https:\/\/akusociety.org\/aku-clinical-trials\/\u0022 rel=\u0022noopener noreferrer\u0022 target=\u0022_blank\u0022\u003Ethree trials\u003C\/a\u003E to test nitisinone across different doses and ages.\u003C\/p\u003E\n\n\u003Cp\u003EThe trials finished in January 2019 and showed that \u003Ca href=\u0022https:\/\/akusociety.org\/wp-content\/uploads\/2021\/02\/Lancet-paper-DevelopAKUre.pdf\u0022 rel=\u0022noopener noreferrer\u0022 target=\u0022_blank\u0022\u003Ethe drug could reduce the homogentisic acid in urine and the body by 99%\u003C\/a\u003E. \u2018I\u2019ve never seen anything in medicine as effective as nitisinone,\u2019 said Prof. Ranganath.\u003C\/p\u003E\n\n\u003Cp\u003EBased on the trial results, the European Medicines Agency (EMA) \u003Ca href=\u0022https:\/\/www.ema.europa.eu\/en\/news\/first-treatment-rare-metabolic-disorder-alkaptonuria#:~:text=EMA%20has%20recommended%20granting%20an,in%20certain%20areas%20of%20Slovakia.\u0022 rel=\u0022noopener noreferrer\u0022 target=\u0022_blank\u0022\u003Eapproved nitisinone\u003C\/a\u003E in September 2020.\u003C\/p\u003E\n\n\u003Cp\u003E\u2018Patients are delighted,\u2019 said Sireau. \u2018People feel a reduction in pain, and they feel that the evolution of their AKU is slowing. Patients are really saying it makes a big difference.\u2019\u003C\/p\u003E\n\n\u003Cp\u003E\u003Cstrong\u003ERepurposing\u003C\/strong\u003E\u003C\/p\u003E\n\n\u003Cp\u003EUsing existing drugs for different conditions is known as repurposing and it offers a lot of promise for treating rare diseases. As they have already been thoroughly tested for safety and side effects, these drugs can be fast-tracked through the early stages of development. However, the expensive large clinical trials needed to show their effectiveness remains the biggest challenge.\u003C\/p\u003E\n\n\u003Cp\u003E\u2018There are problems regarding the incentives with companies that produce these drugs, especially when these drugs are already out of patent,\u2019 said Dr Lucia Monaco, chair of the \u003Ca href=\u0022https:\/\/irdirc.org\/\u0022 rel=\u0022noopener noreferrer\u0022 target=\u0022_blank\u0022\u003EInternational Rare Diseases Research Consortium\u003C\/a\u003E. \u2018There might be very limited interest in doing (a clinical trial) for a drug that perhaps has already produced a return on investment, and there is no need to invest more.\u2019\u003C\/p\u003E\n\n\u003Cp\u003EThe DevelopAKUre trial partnered with SOBI, the pharmaceutical company that held the patent for nitisinone. SOBI\u2019s right to exclusively market nitisinone expired in 2017, partway through the trial, which meant that any company could manufacture a generic version.\u003C\/p\u003E\n\n\u003Cp\u003E\u2018If you put yourself in their shoes, it\u2019s very unattractive to develop a drug knowing that you\u2019re not going to reap the direct benefits,\u2019 said Prof. Ranganath.\u003C\/p\u003E\n\n\u003Cp\u003EHowever, with the help of the AKU Society, SOBI was persuaded to provide the drug for free for the trial. Perhaps more importantly, they also offered their expertise in getting the drug approved by the EMA.\u003C\/p\u003E\n\n\u003Cp\u003E\u2018We did not have in-house scientific and the technical expertise to submit an EMA application,\u2019 said Prof. Ranganath. \u2018I think the role of a pharmaceutical company is quite important here and we were just lucky that way.\u2019\u003C\/p\u003E\n\n\u003Cp\u003E\u2018This is where you get this divide between the competencies of an academic setting and the competencies of a company,\u2019 said Dr Monaco.\u003C\/p\u003E\n\n\u003Cp\u003EThe International Rare Diseases Research Consortium has set a target of getting \u003Ca href=\u0022https:\/\/irdirc.org\/about-us\/vision-goals\/\u0022 rel=\u0022noopener noreferrer\u0022 target=\u0022_blank\u0022\u003E1,000 new treatments for rare diseases approved by 2027\u003C\/a\u003E. Dr Monaco says that repurposing will play an important role in hitting that target, despite the challenges to overcome with collaboration between academia and industry.\u003C\/p\u003E\n\n\u003Cp\u003E\u2018I think the AKU story is exemplar. I think that the role of patients and patient families is crucial, because they have the strongest drive to stimulate this journey and they can really be key to success.\u2019\u003C\/p\u003E\n\n\u003Cp\u003E\u003Cem\u003EThe research in this article was funded by the EU. If you liked this article, please consider sharing it on social media.\u003C\/em\u003E\u003C\/p\u003E\n\n\u003Cp\u003E\u003Cem\u003EThis article was originally published on 26 February 2021.\u003C\/em\u003E\u003C\/p\u003E\n\u003C\/textarea\u003E\n\u003C\/div\u003E\n\n            \u003Cdiv id=\u0022edit-body-content--description\u0022 class=\u0022ecl-help-block description\u0022\u003E\n      Please copy the above code and embed it onto your website to republish.\n    \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003Cinput autocomplete=\u0022off\u0022 data-drupal-selector=\u0022form-qghijgw7x0hbtkz1tzdwbp5nuhnd5s9g9fqdcixvdz4\u0022 type=\u0022hidden\u0022 name=\u0022form_build_id\u0022 value=\u0022form-QGhIjGw7X0hBTKz1tZDWBp5NUhND5s9g9fQdCixVdz4\u0022 \/\u003E\n\u003Cinput data-drupal-selector=\u0022edit-modal-form-example-modal-form\u0022 type=\u0022hidden\u0022 name=\u0022form_id\u0022 value=\u0022modal_form_example_modal_form\u0022 \/\u003E\n\u003C\/form\u003E\n\u003C\/div\u003E","dialogOptions":{"width":"800","modal":true,"title":"Republish this content"}}]